ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth - Regular Plan

  • Previous Nav

  • Net Change on 24-01-2020

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

To generate long-term capital appreciation by creating a portfolio that is invested in Equity and Equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.However there can be no assurance that the investment objectives of the scheme will be realized.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
S&P BSE Health Care 5.31 9.47 0.79 -1.86 -1.87 13.44

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 2.92 5.79 3.90 2.07 2,416.99
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 1.55 -2.14 -0.08 2.40 926.47
UTI Healthcare Fund - Regular Plan - Growth Option Aug 01, 2005 4.57 0.79 0.00 2.36 394.61

Fund Holdings as on 31-December-2019

  • Cipla Ltd.

  • Sun Pharmaceutical Industries Ltd.

  • Biocon Ltd.

  • Cadila Healthcare Ltd.

  • Lupin Ltd.

  • Dr. Reddy's Laboratories Ltd.

  • Sanofi India Ltd.

  • Torrent Pharmaceuticals Ltd.

  • Divi's Laboratories Ltd.

  • Laurus Labs Ltd.

  • IPCA Laboratories Ltd.

  • J.B.Chemicals & Pharmaceuticals Ltd.

  • SBI Life Insurance Company Ltd.

  • Narayana Hrudayalaya Ltd.

  • TREPS

  • Alembic Pharmaceuticals Ltd.

  • Indoco Remedies Ltd.

  • Natco Pharma Ltd.

  • Aster DM Healthcare Ltd.

  • Tata Chemicals Ltd.

  • Alkem Laboratories Ltd.

  • Dishman Carbogen Amcis Ltd.

  • Astrazeneca Pharma India Ltd.

  • Fortis Healthcare Ltd.

  • Panacea Biotec Ltd.

  • FDC Ltd.

  • Syngene International Ltd.

  • Gufic Biosciences Ltd.

  • Neuland Laboratories Ltd.

  • Healthcare Global Enterprises Ltd.

  • Neogen Chemicals Ltd.

  • Max India Ltd.

  • Net Current Assets

View More
  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Insurance

  • Miscellaneous

  • Chemicals

  • Finance - Investment

View More

About ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund

Scheme Analysis

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to ICICI Prudential Mutual Fund. It was launched on 13-Jul-2018 and currently has an AUM of ₹1,286.90 crore. ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is benchmarked against NIFTY 50 - TRI as primary index and S&P BSE Health Care as secondary index.

The NAV of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund ended down ₹-0.02(-0.19%)yesterday to ₹10.79.

Among its top 3 holdings the fund has exposure to Cipla Ltd., and

The ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is managed by Ihab Dalwai and Priyanka Khandelwal.

Fund House Contact

One BKC, A - Wing 13th Floor, Bandra Kurla Complex, Bandra (East) Mumbai - 400 051

+91 (22) 2652 5000
enquiry@icicipruamc.com
+91 (22) 2652 8100